BCG-loaded chitosan microparticles: interaction with macrophages and preliminary in vivo studies

References

• Abebe F, Bjune G. The protective role of antibody responses during Mycobacterium tuberculosis infection. Clin Exp Immunol, 2009;157(2):235–43.
   PubMed Web of Science ®Google Scholar
• Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. Targeting to macrophages: Role of physicochemical properties of particulate carriers: liposomes and microspheres on the phagocytosis by macrophages. J Control Release, 2002;79(1–3):29–40.
   PubMed Web of Science ®Google Scholar
• Aldwell FE, Cross ML, Fitzpatrick CE, Lambeth MR, de Lisle GW, Buddle BM. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis. Vaccine, 2006;24(12):2071–8.
   PubMed Web of Science ®Google Scholar
• Aldwell FE, Keen DL, Parlane NA, Skinner MA, de Lisle GW, Buddle BM. Oral vaccination with Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in brushtail possums. Vaccine, 2003;22(1):70–6.
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target, 1996;3(6):455–67.
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Alpar HO, Brown M. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(l-lactic acid) microspheres in rats, rabbits and Guinea-pigs. J Pharm Pharmacol, 1993;45(3):198–203.
   PubMed Web of Science ®Google Scholar
• Almeida AJ, Florindo HF. 2012. Nanocarriers overcoming the nasal barriers: Physiological considerations and mechanistic issues. In: Alonso MJ, Csaba NS, eds. Nanostructured biomaterials for overcoming biological barriers. Wakefield, United Kingdom: The Charlesworth Group, pp. 117–33.
   Google Scholar
• Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev, 2010;62(1):59–82.
   PubMed Web of Science ®Google Scholar
• Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun, 2008;76(6):2448–55.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol, 2010;10(11):787–96.
   PubMed Web of Science ®Google Scholar
• Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, Chatfield S, Roberts M. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun, 2000;68(10):5764–70.
   PubMed Web of Science ®Google Scholar
• Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine, 2003;21(25–26):3837–44.
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Pires N, Carmo N, Anes E. 2010. Application of confocal microscopy for quantification of intracellular mycobacteria in macrophages. In: Méndez-Vilas A, Díaz J, eds. Microscopy: Science, technology, applications and education. pp. 614–21.
   Google Scholar
• Bhatt K, Salgame P. Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol, 2007;27(4):347–62.
   PubMed Web of Science ®Google Scholar
• Borges O. 2007. Alginate coated chitosan nanoparticles as adjuvant for mucosal vaccination with hepatitis B antigen. Coimbra: Coimbra University.
   Google Scholar
• Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm, 2008;69(2):405–16.
   PubMed Web of Science ®Google Scholar
• Borges O, Silva M, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int Immunopharmacol, 2008;8(13–14):1773–80.
   PubMed Web of Science ®Google Scholar
• Brandhonneur N, Chevanne F, Vié V, Frisch B, Primault R, Le Potier MF, Le Corre P. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci, 2009;36(4–5):474–85.
   PubMed Web of Science ®Google Scholar
• Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine, 2007;25(30):5467–84.
   PubMed Web of Science ®Google Scholar
• Cadete A, Figueiredo L, Lopes R, Calado CC, Almeida AJ, Gonçalves LM. Development and characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate nanoparticles. Eur J Pharm Sci, 2012;45(4):451–8.
   PubMed Web of Science ®Google Scholar
• Caetano LA, Almeida AJ, Gonçalves LMD. Effect of experimental parameters on alginate/chitosan microparticles for BCG encapsulation. Mar Drugs, 2016;14(5):90.
   Web of Science ®Google Scholar
• Caetano LA, Amaral R, Figueiredo L. Chitosan–alginate microparticulate delivery system for an alternative route of administration of BCG vaccine. In Bioeng (ENBENG), 2013 IEEE 3rd Port Meet, 2013;1–3.
   Google Scholar
• Cannon GJ, Swanson JA. The macrophage capacity for phagocytosis. J Cell Sci, 1992;101:907–13.
   PubMed Web of Science ®Google Scholar
• Cevher E, Salomon SK, Makrakis A, Li XW, Brocchini S, Alpar HO. Development of chitosan–pullulan composite nanoparticles for nasal delivery of vaccines: Optimisation and cellular studies. J Microencapsul, 2015;32(8):755–68.
   PubMed Web of Science ®Google Scholar
• Champion J, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res, 2008;25(8):1815–21.
   PubMed Web of Science ®Google Scholar
• Clark S, Cross ML, Smith A, Court P, Vipond J, Nadian A, Hewinson RG, Batchelor HK, Perrie Y, Williams A, et al. Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette–Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis. Vaccine, 2008;26(46):5791–7.
   PubMed Web of Science ®Google Scholar
• Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol, 2009;27:393–422.
   PubMed Web of Science ®Google Scholar
• Corthésy B. Role of secretory immunoglobulin A and secretory component in the protection of mucosal surfaces. Future Microbiol, 2010;5(5):817–29.
   PubMed Web of Science ®Google Scholar
• Dodane V, Amin Khan M, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm, 1999;182(1):21–32.
   PubMed Web of Science ®Google Scholar
• Dorer DE, Czepluch W, Lambeth MR, Dunn AC, Reitinger C, Aldwell FE, McLellan AD. Lymphatic tracing and T cell responses following oral vaccination with live Mycobacterium bovis (BCG). Cell Microbiol, 2007;9(2):544–53.
   PubMed Web of Science ®Google Scholar
• Esquisabel A, Hernandez RM, Igartua M, Gascón AR, Calvo B, Pedraz JL. Preparation and stability of agarose microcapsules containing BCG. J Microencapsul, 2002;19(2):237–44.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, 1997. Note for guidance on preclinical pharmacological and toxicological testing of vaccines.
   Google Scholar
• Figueiredo L, Cadete A, Gonçalves LM, Corvo ML, Almeida AJ. Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems. Vaccine, 2012;30(46):6551–8.
   PubMed Web of Science ®Google Scholar
• Figueiredo L, Calado CCR, Almeida AJ. Protein and DNA nanoparticulate multiantigenic vaccines against H. pylori: In vivo evaluation. In Bioeng (ENBENG), 2012 IEEE 2nd Port Meet, 2012;1.
   Google Scholar
• Florindo HF, Pandit S, Gonçalves LM, Alpar HO, Almeida AJ. New approach on the development of a mucosal vaccine against strangles: Systemic and mucosal immune responses in a mouse model. Vaccine, 2009;27(8):1230–41.
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm, 2005;298(2):315–22.
   PubMed Web of Science ®Google Scholar
• Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ. Multifunctional, high level cytoquine producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol, 2008;181:4955–64.
   PubMed Web of Science ®Google Scholar
• Gerdts V, Littel-van den Hurk Sv, Griebel PJ, Babiuk LA. Use of animal models in the development of human vaccines. Future Microbiol, 2007;2(6):667–75.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of Tcell immunity: Implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines, 2003;3(1):23–34.
   Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev, 2001;51(1–3):81–96.
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Watts P, Smith A. Chitosan-based delivery systems for mucosal vaccines. Expert Opin Drug Deliv, 2012;9(9):1051–67.
   PubMed Web of Science ®Google Scholar
• Jordao L, Bleck CK, Mayorga L, Griffiths G, Anes E. On the killing of mycobacteria by macrophages. Cell Microbiol, 2008;10(2):529–48.
   PubMed Web of Science ®Google Scholar
• Källenius G, Pawlowski A, Brandtzaeg P, Svenson S. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis (Edinb), 2007;87(4):257–66.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Future vaccination strategies against tuberculosis: Thinking outside the box. Immunity, 2010;33(4):567–77.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Hess J. Immune response against Mycobacterium tuberculosis: Implications for vaccine development. J Biotechnol, 2000;83(1–2):13–17.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Hussey G, Lambert P-H. New vaccines for tuberculosis. The Lancet, 2010;375(9731):2110–19.
   PubMed Web of Science ®Google Scholar
• Kaveh DA, Carmen Garcia-Pelayo M, Hogarth PJ. Persistent BCG bacilli perpetuate CD4 T effector memory and optimal protection against tuberculosis. Vaccine, 2014;32(51):6911–18.
   PubMed Web of Science ®Google Scholar
• Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci, 2011;11(6):748–64.
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev, 2009;61(2):158–71.
   PubMed Web of Science ®Google Scholar
• Leithner K, Bernkop-Schnürch A. 2012. Chitosan and derivatives for biopharmaceutical use: Mucoadhesive properties. In: Sarmento B, Neves J, eds. Chitosan-based systems for biopharmaceuticals. West Sussex, United Kingdom: John Wiley & Sons, Ltd, pp. 159–80.
   Google Scholar
• Moghimi SM, Parhamifar L, Ahmadvand D, Wibroe PP, Andresen TL, Farhangrazi ZS, Hunter AC. Particulate systems for targeting of macrophages: Basic and therapeutic concepts. J Innate Immun, 2012;4(5–6):509–28.
   PubMed Web of Science ®Google Scholar
• Mohanan D, Slütter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, Kündig TM, Gander B, Johansen P. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. J Control Release, 2010;147(3):342–9.
   PubMed Web of Science ®Google Scholar
• Olsen AW, Brandt L, Agger EM, van Pinxteren LA, Andersen P. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand J Immunol, 2004;60(3):273–7.
   PubMed Web of Science ®Google Scholar
• Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine, 2012;30(2):142–54.
   PubMed Web of Science ®Google Scholar
• Pawlak A, Mucha M. Thermogravimetric and FTIR studies of chitosan blends. Thermochim Acta, 2003;396(1–2):153–66.
   Web of Science ®Google Scholar
• Pirouzmand H, Khameneh B, Tafaghodi M. Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid. Pharm Biol, 2017;55(1):212–17.
   PubMed Web of Science ®Google Scholar
• Porporatto C, Bianco ID, Correa SG. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J Leukoc Biol, 2005;78(1):62–9.
   PubMed Web of Science ®Google Scholar
• Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, Illum L, Jennings R. Effective nasal influenza vaccine delivery using chitosan. Vaccine, 2005;23(35):4367–74.
   PubMed Web of Science ®Google Scholar
• Reljic R, Williams A, Ivanyi J. Mucosal immunotherapy of tuberculosis: Is there a value in passive IgA? Tuberculosis (Edinb), 2006;86(3–4):179–90.
   PubMed Web of Science ®Google Scholar
• Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol, 2010;13(1):106–12.
   PubMed Web of Science ®Google Scholar
• Rodrigues MA, Figueiredo L, Padrela L, Cadete A, Tiago J, Matos HA, Gomes de Azevedo E, Florindo HF, Gonçalves LM, Almeida AJ. Development of a novel mucosal vaccine against strangles by supercritical enhanced atomization spray-drying of Streptococcus equi extracts and evaluation in a mouse model. Eur J Pharm Biopharm, 2012;82(2):392–400.
   PubMed Web of Science ®Google Scholar
• Sarmento B, Ferreira D, Veiga F, Ribeiro A. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym, 2006;66(1):1–7.
   Web of Science ®Google Scholar
• Sarmento B, das Neves J, eds. 2012. Chitosan-based systems for biopharmaceuticals: Delivery, targeting and polymer therapeutics, 1st edn. West Sussex, United Kingdom: John Wiley & Sons, Ltd.
   Google Scholar
• Simsek-Ege FA, Bond GM, Stringer J. Polyelectrolye complex formation between alginate and Chitosan as a function of pH. J Appl Polym Sci, 2003;88(2):346–51.
   Web of Science ®Google Scholar
• Slütter B, Hagenaars N, Jiskoot W. Rational design of nasal vaccines. J Drug Target, 2008;16(1):1–17.
   PubMed Web of Science ®Google Scholar
• Szymańska E, Winnicka K. Stability of chitosan-a challenge for pharmaceutical and biomedical applications. Mar Drugs, 2015;13(4):1819–46.
   PubMed Web of Science ®Google Scholar
• Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release, 2001;76(1–2):59–71.
   PubMed Web of Science ®Google Scholar
• Vajdy M, O’Hagan DT. Microparticles for intranasal immunization. Adv Drug Deliv Rev, 2001;51(1–3):127–41.
   PubMed Web of Science ®Google Scholar
• Vicente S, Diaz-Freitas B, Peleteiro M, Sanchez A, Pascual DW, Gonzalez-Fernandez A, Alonso MJ. A polymer/oil based nanovaccine as a single-dose immunization approach. PLoS One, 2013;8(4):e62500.
   PubMed Web of Science ®Google Scholar
• Vila A, Sánchez A, Evora C, Soriano I, McCallion O, Alonso MJ. PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm, 2005;292:43–52.
   PubMed Web of Science ®Google Scholar
• WHO 2011/2012 Tuberculosis Global Facts Factsheet. Geneva: World Health Organization, 2012.
   Google Scholar
• WHO guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines. WHO Expert Committee on Biological Standardization. Geneva: World Health Organization, 2014.
   Google Scholar
• Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivery. Annu Rev Biomed Eng, 2012;14:17–46.
   PubMed Web of Science ®Google Scholar
• Xing Z. Importance of T-cell location rekindled: Implication for tuberculosis vaccination strategies. Expert Rev Vaccines, 2009;8(11):1465–8.
   PubMed Web of Science ®Google Scholar